MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Atkinson, B. N.
Right arrow Articles by Klitenick, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atkinson, B. N.
Right arrow Articles by Klitenick, M. A.

Vol. 60, Issue 6, 1414-1420, December 2001

ALX 5407: A Potent, Selective Inhibitor of the hGlyT1 Glycine Transporter

B. N. Atkinson, S. C. Bell, M. De Vivo, L. R. Kowalski, S. M. Lechner, V. I. Ognyanov, C.-S. Tham, C. Tsai, J. Jia, D. Ashton, and M. A. Klitenick

Allelix Neuroscience, Inc., Cranbury, New Jersey (B.N.A., S.C.B., M.DV., L.R.K., S.M.L., V.I.O., C-S.T., C.T., J.J., M.A.K.); and Central Nervous System Discovery Research, Janssen Research Foundation, Beerse, Belgium (A.D.)

High-affinity glycine transport in neurons and glial cells is a primary means of inactivating synaptic glycine. We have synthesized a potent selective inhibitor of glycine transporter 1 (GlyT1), and characterized its activity using a quail fibroblast cell line (QT6). The glycine transporters GlyT1A, GlyT1B, GlyT1C, and GlyT2 were stably expressed in QT6 cells. The transporters expressed in these cells exhibited appropriate characteristics as described previously for these genes: Na+/Cl- dependence, appropriate Km values for glycine uptake, and appropriate pharmacology, as defined in part by the ability of N-methyl glycine (sarcosine) to competitively inhibit glycine transport. Furthermore, the characteristics of the transporters in the cell lines recapitulate the characteristics of glycine transporters observed in tissue preparations. We developed a sarcosine derivative, (R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine (ALX 5407), and examined its activity against the cloned glycine transporters. ALX 5407 completely inhibited glycine transport in the GlyT1 cells, with an IC50 value of 3 nM, but had little or no activity at the human GlyT2 transporter, at other binding sites for glycine, or at other neurotransmitter transporters. The inhibition of glycine transport was essentially irreversible. ALX 5407 represents a novel tool in the investigation of N-methyl-D-aspartate-receptor function. This class of drug may lead to novel therapies in the treatment of schizophrenia.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
M. Mezler, W. Hornberger, R. Mueller, M. S. W. Amberg, W. Braje, M. Ochse, H. Schoemaker, and B. Behl
Inhibitors of GlyT1 Affect Glycine Transport via Discrete Binding Sites
Mol. Pharmacol., December 1, 2008; 74(6): 1705 - 1715.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
P. J. Conn, C. Tamminga, D. D. Schoepp, and C. Lindsley
Schizophrenia: Moving Beyond Monoamine Antagonists
Mol. Interv., April 1, 2008; 8(2): 99 - 107.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Schizophr Bull, September 1, 2007; 33(5): 1120 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. J. Vandenberg, K. Shaddick, and P. Ju
Molecular Basis for Substrate Discrimination by Glycine Transporters
J. Biol. Chem., May 11, 2007; 282(19): 14447 - 14453.
[Abstract] [Full Text] [PDF]

Home page
 NeuroscientistHome page
C. R. Yang and L. Chen
Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment
Neuroscientist, October 1, 2005; 11(5): 452 - 470.
[Abstract] [PDF]

Home page
 J. Physiol.Home page
H. Huang, L. Barakat, D. Wang, and A. Bordey
Bergmann glial GlyT1 mediates glycine uptake and release in mouse cerebellar slices
J. Physiol., November 1, 2004; 560(3): 721 - 736.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. G. Kinney, C. Sur, M. Burno, P. J. Mallorga, J. B. Williams, D. J. Figueroa, M. Wittmann, W. Lemaire, and P. J. Conn
The Glycine Transporter Type 1 Inhibitor N-[3-(4'-Fluorophenyl)-3-(4'-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior
J. Neurosci., August 20, 2003; 23(20): 7586 - 7591.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
L. Chen, M. Muhlhauser, and C. R. Yang
Glycine Tranporter-1 Blockade Potentiates NMDA-Mediated Responses in Rat Prefrontal Cortical Neurons In Vitro and In Vivo
J Neurophysiol, February 1, 2003; 89(2): 691 - 703.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics